A proposed securities class action against Ardelyx covers investors who bought its securities from January 13, 2025 through August 6, 2026, with a November 16, 2026 deadline to seek lead-plaintiff appointment. Portnoy Law Firm said the complaint asserts claims under Section 10(b) of the Exchange Act, Rule 10b-5 and Section 20(a), alleging that four executive defendants controlled allegedly misleading statements about long-term sales projections for IBSRELA and XPHOZAH, commercial-access strategy and barriers to patient adoption. The Ardelyx matter is separate from proposed actions involving Baidu, Dun & Bradstreet Holdings and Beta Bionics. Those cases carry lead-plaintiff deadlines of November 13, November 10 and November 3, 2026, respectively. No class has been certified in the reported actions.